Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes

被引:165
作者
Schäkel, K [1 ]
Kietzell, M
Haensel, A
Ebling, A
Schulze, L
Haase, M
Semmler, C
Sarfati, M
Barclay, AN
Randolph, GJ
Meurer, M
Rieber, EP
机构
[1] Tech Univ Dresden, Inst Immunol, D-01307 Dresden, Germany
[2] Tech Univ Dresden, Dept Dermatol, D-01307 Dresden, Germany
[3] Tech Univ Dresden, Fac Med, Inst Pathol, D-01307 Dresden, Germany
[4] CHU Montreal, Notre Dame Hosp, Res Ctr, Montreal, PQ H2L 4M1, Canada
[5] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England
[6] CUNY Mt Sinai Sch Med, Icahn Res Inst, Dept Gene & Cell Med, New York, NY 10029 USA
基金
英国医学研究理事会;
关键词
D O I
10.1016/j.immuni.2006.03.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Early and high-level production of IL-12 is crucial for effective immune responses against pathogens. Up until now, the cells providing this initial IL-12 have remained elusive. Here we show that a subset of human blood dendritic cells (DC) is the principal and primary source of IL-12p70 when blood leukocytes are stimulated with the TILR4-ligand LPS or with CD40-ligand. These so-called slanDC are characterized by the 6-sulfo LacNAc modification of PSGL-1, which is identified by the mAb M-DC8. The IL-12 response of slanDC requires a few hours of in vitro maturation, which is completely blocked in the presence of erythrocytes. This inhibition of maturation depends on the expression of CD47 on erythrocytes and of its ligand SIRP alpha on DC. While strictly controlled in the blood by erythrocytes, the high IL-12- and TNF-alpha-producing capacity of slanDC in tissues may be critical in fighting off pathogens; if uncontrolled, it may lead to adverse inflammatory reactions.
引用
收藏
页码:767 / 777
页数:11
相关论文
共 41 条
[1]   Red blood cells inhibit apoptosis of human neutrophils [J].
Aoshiba, K ;
Nakajima, Y ;
Yasui, S ;
Tamaoki, J ;
Nagai, A .
BLOOD, 1999, 93 (11) :4006-4010
[2]   Red blood cells as modulators of T cell growth and survival [J].
Arosa, FA ;
Pereira, CF ;
Fonseca, AM .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (02) :191-201
[3]   Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family [J].
Brooke, G ;
Holbrook, JD ;
Brown, MH ;
Barclay, AN .
JOURNAL OF IMMUNOLOGY, 2004, 173 (04) :2562-2570
[4]   PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J].
CASEY, LC ;
BALK, RA ;
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :771-778
[5]   Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].
Chaudhari, U ;
Romano, P ;
Mulcahy, LD ;
Dooley, LT ;
Baker, DG ;
Gottlieb, AB .
LANCET, 2001, 357 (9271) :1842-1847
[6]  
COHEN J, 1995, SCIENCE, V270, P908
[7]   A subset of human dendritic cells in the T cell area of mucosa-associated lymphoid tissue with a high potential to produce TNF-α [J].
de Baey, A ;
Mende, I ;
Baretton, G ;
Greiner, A ;
Hartl, WH ;
Baeuerle, PA ;
Diepolder, HM .
JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :5089-5094
[8]   RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].
ELLIOTT, MJ ;
MAINI, RN ;
FELDMANN, M ;
KALDEN, JR ;
ANTONI, C ;
SMOLEN, JS ;
LEEB, B ;
BREEDVELD, FC ;
MACFARLANE, JD ;
BIJL, H ;
WOODY, JN .
LANCET, 1994, 344 (8930) :1105-1110
[9]   Red blood cells promote survival and cell cycle progression of human peripheral blood T cells independently of CD58/LFA-3 and heme compounds [J].
Fonseca, AM ;
Pereira, CF ;
Porto, G ;
Arosa, FA .
CELLULAR IMMUNOLOGY, 2003, 224 (01) :17-28
[10]   Red blood cells inhibit activation-induced cell death and oxidative stress in human peripheral blood T lymphocytes [J].
Fonseca, AM ;
Porto, G ;
Uchida, K ;
Arosa, FA .
BLOOD, 2001, 97 (10) :3152-3160